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Abstract
Background: The association of genetic polymorphisms related to metabolism of homocysteine
with inflammatory bowel disease has been evidenced in Crohn disease and remains an open
question in ulcerative colitis. We evaluated the association of the polymorphisms of MTHFR, MTR,
MTRR and TCN2 genes with ulcerative colitis in Central China.
Methods: 168 patients were genotyped for these polymorphisms and compared to 219 matched
controls.
Results: Methionine synthase 2756G allele frequency was higher in ulcerative colitis than in controls
0.15 (95% C.I. 0.11–0.19) vs 0.09 (95% C.I. 0.07 – 0.12), (P = 0.0137) and predicted ulcerative colitis
risk in logistic regression, with an Odds ratio at 1.8 (95% C.I. 1.15–2.84). Methylenetetrahydrofolate
reductase 677TT genotype was 2.7-fold more prevalent in individuals with pancolitis than in those
with left colitis or proctitis, with respective percentages of 27.3 (95% C.I.16.4–42.0) and 10.5 (95%
C.I. 6.3–17.1) (P = 0.0123). The carriage of 677TT or 677CT/1298AC genotypes of
methylenetetrahydrofolate reductase was more frequent in cases with pancolitis than in subjects with
left colitis or proctitis (P = 0.0048), with an Odds ratio adjusted by age and sex at 3.3 (95% C.I. 1.4–
7.9), P = 0.0084) in logistic regression.
Conclusion: Methionine synthase and methylenetetrahydrofolate reductase are genes of vitamin B12
and folate cellular metabolism associated respectively with risk and extent of ulcerative colitis, at
least in Central China. This finding may open new insights, particularly for the potential interest in
treating patients carrying the 677TT MTHFR genetic trait and a deficit in folate.
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Background
Homocysteine is a key metabolite of the one carbone
metabolism, at the cross point between the remethylation
pathway that produces methionine and the transulfura-
tion pathway that produces cysteine [1]. Plasma homo-
cysteine (t-Hcys) is influenced by genetic polymorphisms
of the key enzymes of the remethylation pathway, methyl-
enetetrahydrofolate reductase (MTHFR C677T) [2,3], methio-
nine synthase (MTR A2756G) [4] and methionine synthase
reductase (MTRR A66G) [5]. MTHFR catalyses the synthe-
sis of methyletetrahydrofolate, the methyl donor of
homocysteine and MTR and MTRR are the two key
enzymes of the synthesis of methionine by remethylation
of homocysteine. The C677T  genetic polymorphism in
the MTHFR gene is found to be associated with a thermo-
labile variant enzyme that shows a reduced activity [2]. A
genetic polymorphism in the transcobalamin gene (TCN2
C776G) is another genetic trait that may influence the
vitamin B12 cellular delivery and consequently, homo-
cysteine metabolism [6]. Transcobalamin is a specific
plasma transporter of cobalamin (vitamin B12) and facil-
itates the cellular uptake of the vitamin by receptor-medi-
ated endocytosis [6].
Hyperhomocysteinemia is recognized as a risk factor for
both venous and arterial thrombosis in the general popu-
lation [7,8]. In this regard, genetic determinants of homo-
cysteine metabolism have received increasing attention
over the past decade as potential contributors to the
greater risk of thrombosis in inflammatory bowel disease
(IBD) subjects [9]. Homocysteine has also a crucial role in
cellular stress, epigenetic events, inflammatory processes
and host-microbial interactions. Hyperhomocysteinemia
might therefore influence the clinical history of IBD,
including disease severity [9]. Mahmud and colleagues
were the first to report a higher prevalence of MTHFR
677T allele in IBD patients, compared to controls [10].
Nevertheless a number of subsequent studies have pro-
duced conflicting results, possibly related with complex
interactions between environmental and genetic factors
[11-17]. Ethnic and geographical variations in the distri-
bution and phenotypic influence of MTHFR variants may
explain, at least in part, discrepancies between case con-
trol studies on the association between MTHFR polymor-
phism and IBD [18,19]. Polymorphisms of other
homocysteine metabolism-related enzymes may also con-
tribute to the link between homocysteine metabolism and
IBD patients. The influence of MTHFR, MTR, MTRR and
TCN2 polymorphisms on the primary and secondary risk
of ulcerative colitis have never been evaluated in a same
sample population. Most of the case-control studies have
evaluated Caucasian populations from North America
and Europe, where the prevalence of Crohn disease is pre-
dominant, in contrast with populations from Asia, where
UC is the most frequent form of IBD. In contrast to
MTHFR 677T allele, the G allele frequency of TCN2 poly-
morphism is dramatically higher in Central China, com-
pared with that reported in Caucasian populations
[16,18,19].
The aim of this study was therefore to evaluate the influ-
ence of genetic determinants of homocysteine metabo-
lism, MTHFR, MTR, MTRR and TCN2 with the primary
risk and the clinical manifestations of UC, in a case con-
trol study of a sample population from Central China.
Methods
Study subjects
Eligible patients were males or females with established
ulcerative colitis UC. 168 patients who were recruited
from one single department (Department of Gastroenter-
ology and Reseach center of Digestive diseases, Zhongnan
Hospital of Wuhan University, Wuhan, province of
Hubei, RP China) were prospectively enrolled in a case-
control study, during a 2-years period. Information
regarding concomitant medications was collected at study
entry. Extent of UC was defined according to Montreal
Classification [20]. The term "Pancolitis" means "ulcera-
tive colitis that involves the entire colon." The UC subjects
were compared to 219 healthy volunteers from a blood
donor Center of Wuhan, who presented without anemia,
abdominal pain, inflammation, diarrhea nor blood in the
stools. The controls were extracted from a larger cohort
and were matched for age and sex with UC patients. All
individuals belonged to Han ethnicity and originated
from the Hubei province, in Central China. This study was
approved by the local ethic committee, and the subjects
included gave informed consent, according to the Hel-
sinki declaration.
Assays and DNA genotyping procedures
Fasting venous blood was collected in EDTA-containing
tubes, immediately centrifuged, and stored at -20°C until
analysis. DNA was isolated from a lymphocyte-enriched
fraction of whole blood with NUCLEON BACC3 for
extraction of genomic DNA kit (Amersham Pharmacia
Biotech, Milan, Italy). The procedures for detecting the
C677T and A1298C polymorphisms of MTHFR, as well as
the A2756G MTR and the A66G MTRR polymorphisms,
were based on polymerase chain reaction (PCR) amplifi-
cation, restriction cleavage and separation of the DNA
fragments by 15% non denaturant polyacrylamide gel
electrophoresis (SDS-PAGE), as previously described
[18,19]. Genotyping of the TCN2 C776G polymorphism
was performed by the amplification-refractory mutation
system, as described recently by us [6]. DNA samples cor-
responding to amplified DNA of the MTHFR, MTR and
MTRR genotypes were sequenced and subsequently used
as controls in all series of genotype determination. Five %
of the samples were re-genotyped to check for genotype
calling consistency, with a genotyping success rate higher
than 98%.BMC Medical Genetics 2008, 9:78 http://www.biomedcentral.com/1471-2350/9/78
Page 3 of 7
(page number not for citation purposes)
Statistical analysis
The tested a priori hypotheses were the association of the
genetic determinants of homocysteine metabolism with
the primary risk and the clinical characteristics of the dis-
ease, respectively. Categorical variables were reported as
counts, percentages and 95% confidence interval, and
continuous variables as means ± SD. For categorical vari-
ables, continuity-corrected chi-square test or exact Fisher
test (when variables were stratified in function of clinical
characteristics) were used to assess differences. For contin-
uous variables, a Mann-Whitney U-test was employed.
The significance, odds ratios (OR) and 95% confidence
interval of independent determinants regarding the risk of
IBD were determined by logistic regression analysis using
a model that included age, sex and the genetic and clinical
variables. The residual model of logistic regression multi-
variate analysis considered only the variables with P-value
< 0.10 in the univariate analysis. The minimal size of our
sample was estimated at 150 patients, with a study power
1-β = 0.8 and α = 0.05, assuming a 1.5-fold difference in
the less frequent alleles between controls and patients. P-
value lower than 0.05 indicated statistical significance and
Bonferroni correction for multiple testing was used as
described previously, when several dependent or inde-
pendent statistical tests were being performed simultane-
ously [18]. (Data were prospectively collected and
analyzed using the Statview 5 software for Windows (SAS
Institute, Berkley, California, USA) and the SPSS 10.0 soft-
ware for Windows (SPSS, Paris, France). HWE was tested
using the chi-square two-tailed calculation of Knud Chris-
tensen, population genetics, www.kursus.kvl.dk.
Results
Clinical characteristics of UC patients
There were no significant difference in sex ratio between
controls and UC patients, with respectively 38% and 42%
of females (P = 0.3660); the age was respectively 41 ± 15
and 41 ± 12 years (P = 0.7428). The age onset was 38 ± 15,
without difference among gender. The main clinical char-
acteristic of the UC patients are summarized in table 1. A
quarter presented with an extensive form of colitis and
about 57% with lesions limited to rectum and/or sig-
moid. None of the cases presented with a reported throm-
boembolic episode.
Comparison of the genetic characteristics of UC patients 
and controls
There was no linkage desequilibrium among different
genotypes. The genotype of MTHFR C677T, A1298C,
MTR, MTRR, and TCN could be determined in respec-
tively 215, 213, 218, 219, 216 of the 219 DNA samples
from controls and in respectively 168, 160, 156, 164, 146
of the 168 DNA samples from UC cases. The genotype dis-
tributions of MTHFR, MTR, MTRR, and TCN polymor-
phisms of patients were in Hardy-Weinberg equilibrium
(P-values of two tailed chi-square 0.5071, 0.8231, 0.3055,
0.7184, 0.4237, respectively) and were not influenced by
gender (data not shown). MTHFR 677T and 1298C alleles
were in complete disequlibrium, as previously reported in
other populations [3].
The genotype distributions of MTHFR, MTRR and TCN
polymorphisms did not differ between controls and UC
patients (table 2). The same observation was made for
allele frequencies (table 2). In contrast, the carriers of
MTR 2756AG/GG genotypes were more frequent in UC
than in the control group, with respective percentages of
26.3 (95% C.I. 20.0–33.7) and 16.5 (12.2–22.0) (P =
0.0212). The same observation was made with the MTR
2756G allele frequency, with a difference even more sig-
nificant (table 2). In logistic regression, carriage of MTR
2756G allele was an independent predictor of UC, with an
Odds ratio estimated at 1.8 (table 2).
Association of genetic polymorphisms with clinical 
characteristics of UC patients
We next examined the association of polymorphisms of
homocysteine metabolism-related enzymes with the clin-
Table 1: Categorical clinical characteristics of the 168 patients with ulcerative colitis.
Characteristic Number of cases Percentage (95% confidence interval)
Male sex 97 57.7 (50.2-57.7)
Past smoking 14 8.3 (5.1–13.5)
Current smoker 12 7.1 (4.2–12.1)
Concomitant medications:
Steroids 50 29.8 (23.4–29.8)
Sulfasalazine 98 58.3 (50.8–65.5)
5-aminosalicylate 69 41.1 (33.9–48.6)
Antibiotics 15 8.9 (5.5–14.2)
Disease location:
Rectum 78 46.4 (39.0–54.0)
Left colon 46 27.4 (21.2–34.6)
Pancolitis 44 26.2 (20.1–33.3)
Personal history of surgery:
Colectomy 2 1.2 (0.4–4.2)BMC Medical Genetics 2008, 9:78 http://www.biomedcentral.com/1471-2350/9/78
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ical characteristics. None of the polymorphisms influ-
enced the age onset of the disease. In univariate analysis,
MTR, MTRR and TCN polymorphisms were not associ-
ated with location and extent of UC while MTHFR 677TT
genotype was associated with pancolitis. The frequency of
the TT genotype of MTHFR C677T polymorphism was
2.7-fold higher in UC individuals with pancolitis than in
other UC cases, with respective percentages of 27.3 (95%
C.I.16.4–42.0) and 10.5 (95% C.I. 6.3–17.1) (P =
0.0123). The frequency of subjects who presented with
either 677TT or the double heterozygous 677CT/1298AC
genotype was also significantly different between subjects
with pancolitis and those with left colitis or proctitis, with
respective percentages of 43.2 (95% C.I. 29.6–43.2) and
20.2 (95% C.I. 14.1–28.1) (P = 0.0048).
Finally, the association of gene polymorphisms of genes
of the remethylation pathway with the risk of pancolitis
was estimated by logistic regression analysis using a
model that included age, sex, medications and genetic
polymorphisms. We confirmed that the only significant
independent gene predictor of extensive lesions was
MTHFR. The sex and age adjusted odds ratio of the associ-
ation between pancolitis and MTHFR 677 TT was esti-
mated to 3.82 (95% C.I. 1.3–11.7, P = 0.0179). When the
age and sex adjusted analysis was performed by consider-
ing the carriers of 677TT or C677CT/1298AC genotypes of
MTHFR instead of MTHFR 677TT only, the same conclu-
sion was reached, with an Odds ratio at 3.3 (95% C.I. 1.4–
7.9, P = 0.0084).
Discussion
Genetic factors possibly associated with ulcerative colitis
remain poorly known. This is the first study that evaluated
the association of genes of the remethylation pathway of
homocysteine, MTHFR, MTR, MTRR and TCN2, in a case
population restricted to UC, in China. It evidenced a sig-
nificant association of MTR and MTHFR variants with the
Table 2: Genotype frequencies and minor allele frequencies of genetic polymorphisms in ulcerative colitis patients and controls.
Controls
Frequencies (%)
UC patients
Frequencies (%)
P-value OR (95% CI)*
MTHFR 677
CC# 40.9 38.1
CT# 43.3 45.2 0.6053a 1.12 (0.72–1.75)
TT 15.8 16.7 0.6821a 1.13 (0.62–2.05)
Total number of patients analysed 215 168
Allele T 0.37 0.39 0.6027 1.09 (0.81–1.46)
MTHFR 1298
AA# 66.2 69.4
AC 29.1 28.1 0.7277a 0.92 (0.58–1.46)
CC 4.7 2.5 0.2631a 0.51 (0.15–1.66)
Total number of patients analysed 213 160
Allele C 0.19 0.17 0.3455 0.86 (0.59–1.26)
MTR 2756
AA# 83.5 73.7
AG 15.1 23.1 0.0422a 1.72 (1.02–2.92)
GG 1.4 3.2 0.1899a 2.64 (0.62–11.25)
Total number of patients analysed 218 156
Allele G 0.09 0.15 0.0137 1.81 (1.15–2.84)
MTRR 66
AA# 58.0 53.7
AG 35.6 38.4 0.4839a 1.17 (0.76–1.79)
GG 6.4 7.9 0.4746a 1.34 (0.60–2.99)
Total number of patients analysed 219 164
Allele G 0.24 0.27 0.2401 1.18 (0.85–1.64)
TCN2 776
CC# 21.8 18.5
CG 38.9 45.2 0.3358a 1.26 (0.79–2.01)
GG 39.3 36.3 0.7835a 1.09 (0.61–1.95)
Total number of patients analysed 216 146
Allele G 0.58 0.59 0.9447 1.0 (0.74–1.35)
*(OR: unadjusted odds ratio; 95 CI%: 95% confidence interval)
Abbreviations :methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methylenetetrahydrofolate reductase (MTRR) and transcobalamin 
(TCN2)
# Dominant genotype. a Comparison with dominant genotype.BMC Medical Genetics 2008, 9:78 http://www.biomedcentral.com/1471-2350/9/78
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primary risk and the extent of the disease, respectively;
677TT and C677CT/1298AC genotypes of MTHFR were
predictors of extensive colitis, while no association was
found with the primary risk of UC. In contrast, MTR
2756G allele was associated with an increased risk of UC
and had no influence on the extent of the disease. MTR
and MTFHR have a complementary role in this pathway.
During the remethylation of homocysteine into methio-
nine, a methyl group provided by 5-methyltetrahydro-
folate (5-methylTHF) is transferred to homocysteine by
MTR. In this remethylation pathway, cobalamin (vitamin
B12) is involved as an intermediate carrier of the methyl
group while the 5-methylTHF is synthesized by MTHFR.
The phenotypic influence of the 2756G allele on the activ-
ity of MTR has not been clearly evidenced [4]. In contrast,
both 677TT and 1298AC/677CT genotypes are known to
produce a decreased catalytic enzyme activity of MTHFR
[2]. Notably, the 677TT genotype of MTHFR is encoding a
thermolabile variant characterized by an alanine to valine
substitution at position 222, and a 50% reduction in
enzyme activity [2]. As a consequence, MTHFR C677T
polymorphism produces a decreased cellular level of
methyl-THF and a cellular accumulation of homo-
cysteine, particularly in patients with insufficient folate
supply [21]. Interestingly, recent experimental findings
raise the possibility that homocysteine-induced cellular
and vascular stress may contribute to the maintenance of
a chronic mucosal inflammatory state in IBD [9,22].
Clinical implications of the MTHFR C677T polymor-
phism include increased risk for several diseases, such as
vascular, neurological and for birth defects [21,23]. Its
phenotypic influence on homocysteine metabolism is
neutral in subjects with sufficient folate supply, as in
South Europe [18]. Similarly, the association of MTHFR
with other diseases than IBD seems to be neutral in South
European countries, where the status of populations in
folate is better than in North Europe, while some studies
have showed association with MTR and MTRR in these
countries [23,24]. This could explain some of the discrep-
ant results produced on association studies with IBD in
populations with contrasted status in folate. Indeed, two
studies performed in Northern Europe reported a signifi-
cant increased frequency of the MTHFR TT genotype
[10,25], whereas four studies in Southern Europe (two
Italian, one French, one Portuguese) and one Chinese
study showed no difference [11,14-17]. In contrast, we
found a higher frequency of MTRR 66A allele in patients
with Crohn's disease compared with controls, and we
observed an influence of this gene variant on the extent of
the disease [26]. We also evidenced that vitamin B12 was
a nutritional determinant of homocysteinemia, that was
under the influence of oxidative stress [26]. Consistently,
a recent report showed that folate deficiency was not a
predictor of homocysteine level in case of increased oxida-
tive stress, underscoring the implication of other nutri-
tional determinants, such as vitamin B12, under
pathological conditions [27]. Taken together, these results
are in agreement with our findings indicating that methio-
nine synthase A2756G polymorphism, a vitamin B12-
dependent enzyme, may predict ulcerative colitis. The
data are also difficult to compare among contrasted pop-
ulations since the frequency of these gene polymorphisms
and their influence on homocysteine fluctuate greatly,
worldwide [18,19]. The prevalence of the homozygous T
allele seems to be influenced by folate status, the preva-
lence being the highest in Mexicans, Chinese and Italians
and the lowest in West Africans [18,19]. It would be there-
fore useful to revisit the studies on IBD and MTHFR that
have been published in Europe by evaluating also the
association with the other gene variants related with the
remethylation pathway. Finally, the discrepancies
observed in previous studies on association between
MTHFR and IBD may also correspond in part to differ-
ences in the proportion of cases with extensive colitis, as
suggested by our observation that MTFHR is a predictor of
pancolitis, at least in UC. This observation was in agree-
ment with our previous study of a smaller series of UC
patients [16]. In addition, the association with severity of
the disease may be related with a deficit in folate and vita-
min B12, as previously observed by us in Caucasians with
Crohn's disease [26]. Vitamin B12 metabolism influenced
Crohn's disease activity by modulating oxidative stress,
measured by superoxide dismutase activity [26]. Homo-
cysteine levels were recently correlated with activity,
number of flares and duration of the disease [28]. Unfor-
tunately, we could not determine the blood level of these
determinants in the present series as no serum or plasma
sample was available. Furthermore, we recently found
that azathioprine therapy decreased plasma homo-
cysteine level [26], suggesting interactions between aza-
thioprine and homocysteine metabolisms. Genetic
variation in the MTHFR gene may result in reduced S-ade-
nosylmethionine concentations, leading to enhanced
TPMT enzyme degradation and possibly modulating aza-
thioprine efficacy [29].
Over the past decade, hyperhomocysteinemia and
MTHFR C677T polymorphism have been regarded solely
as potential contributors to the greater risk of thrombosis
in IBD [14,15,30-32]. Our data indicated clearly that it
influenced the severity of UC, independently of the risk of
thrombosis, as none of the case from our series underwent
a thrombosis episode.
Conclusion
MTR and MTHFR are two genes of vitamin B12 and folate
cellular metabolism associated respectively with the pri-
mary risk and the severity of UC, at least in central China.
These findings might open new insights into the patho-BMC Medical Genetics 2008, 9:78 http://www.biomedcentral.com/1471-2350/9/78
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genesis and assessment of UC, particularly for the poten-
tial interest in treating the patients presenting with the
677TT MTHFR genetic trait and a deficit in folate. How-
ever, our results await confirmation in a large cohort of
patients with UC.
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